Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
評估G1療法：來自5位金融分析師的見解
In examining recent...Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on G1 Therapeutics (NASDAQ:GTHX) in the last three months.
在過去三個月中，有5位分析師公佈了對G1 Therapeutics（納斯達克股票代碼：GTHX）的評級，提供了從看漲到看跌的不同視角。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表彙總了他們最近的評級，闡明瞭過去30天內情緒的變化，並將其與前幾個月進行了比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.4, a high estimate of $12.00, and a low estimate of $4.00. This upward trend is apparent, with the current average reflecting a 9.47% increase from the previous average price target of $9.50.
分析師評估的12個月目標股價揭示了進一步的見解，平均目標價爲10.4美元，最高估計爲12.00美元，低估值爲4.00美元。這種上升趨勢顯而易見，當前的平均價格較之前的平均目標價9.50美元上漲了9.47％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析師評級：詳細審查
In examining recent...
在研究...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間